Profile data is unavailable for this security.
About the company
Moberg Pharma AB (publ), formerly Moberg Derma AB (publ) is a Sweden-based pharmaceutical company. The Company is a pharmaceutical company in dermatology focused on the commercialization of proprietary drugs based on proven substances. Moberg Pharma AB (publ) develops MOB-015, the treatment of nail fungus. Its product portfolio includes products for the treatment of skin diseases, pain, the treatment of nails damaged by fungus or psoriasis, dry and damaged feet and range of products for several types of skin and scalp problems. The Company deals with development, manufacture, direct and indirect sale, marketing and licensing of pharmaceuticals, medical devices and skin care products as well as related activities.
- Revenue in SEK (TTM)12.50m
- Net income in SEK-257.79m
- Incorporated2006
- Employees6.00
- LocationMoberg Pharma AB (publ)Gustavslundsvagen 42, 5 tr.BROMMA 167 51SwedenSWE
- Phone+46 852230700
- Fax+46 87352029
- Websitehttps://www.mobergpharma.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vivesto AB | 0.00 | -35.72m | 101.37m | 4.00 | -- | 0.3795 | -- | -- | -0.0664 | -0.0664 | 0.00 | 0.2483 | 0.00 | -- | -- | 0.00 | -21.35 | -- | -23.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.12 | -- | -- | -- |
| IRLAB Therapeutics AB | 85.56m | -91.91m | 155.80m | 31.00 | -- | 2.88 | -- | 1.82 | -1.56 | -1.56 | 1.40 | 0.6382 | 0.5172 | -- | 8.93 | 3,168,815.00 | -55.56 | -27.34 | -149.51 | -32.01 | -35.80 | -45.70 | -107.43 | -112.19 | -- | -4.29 | 0.3548 | -- | 1,566.57 | 415.48 | 53.26 | -- | 7.75 | -- |
| Isofol Medical AB (publ) | 0.00 | -54.49m | 169.51m | 6.00 | -- | 1.41 | -- | -- | -0.2698 | -0.2698 | 0.00 | 0.4291 | 0.00 | -- | -- | 0.00 | -43.21 | -61.58 | -51.19 | -82.71 | -- | -740.36 | -- | -861.94 | -- | -- | 0.00 | -- | -100.00 | -- | -17.31 | -- | -- | -- |
| Magle Chemoswed Holding AB | 292.44m | -26.60m | 225.08m | 144.00 | -- | 0.4233 | 8.12 | 0.7697 | -1.29 | -1.29 | 14.56 | 25.75 | 0.3085 | -0.0596 | 8.14 | 1,989,374.00 | -2.81 | 2.43 | -3.45 | 3.45 | 102.66 | 88.63 | -9.09 | 4.76 | 0.8205 | -0.1043 | 0.3887 | 0.00 | 38.49 | 13.10 | -1.91 | 74.06 | -21.72 | -- |
| Elicera Therapeutics AB | 13.70m | -13.04m | 228.12m | 2.00 | -- | 7.44 | -- | 16.66 | -0.3434 | -0.3434 | 0.3712 | 0.6314 | 0.4004 | -- | 9.61 | 6,848,050.00 | -38.14 | -42.99 | -48.58 | -55.48 | -- | -- | -95.24 | -345.69 | -- | -- | 0.00 | -- | -36.52 | -- | 1.75 | -- | -- | -- |
| Lipum AB (publ) | 0.00 | -76.37m | 290.61m | 6.00 | -- | -- | -- | -- | -3.60 | -3.60 | 0.00 | -1.33 | 0.00 | -- | -- | 0.00 | -179.79 | -146.87 | -660.20 | -220.28 | -- | -- | -- | -1,379,275.00 | -- | -39.82 | 3.77 | -- | -- | -- | -49.32 | -- | -- | -- |
| Biohit Oyj | 166.26m | 28.59m | 377.93m | 46.00 | 16.43 | 2.98 | 10.50 | 2.27 | 0.1778 | 0.1778 | 1.03 | 0.9804 | 0.8895 | 5.36 | 4.61 | 341,304.30 | 15.86 | 9.67 | 19.52 | 12.32 | 68.79 | 65.69 | 17.83 | 9.82 | 2.31 | -- | 0.097 | 0.00 | 9.92 | 17.12 | 5.14 | -- | 109.13 | -- |
| Corline Biomedical AB | 7.56m | -23.85m | 412.38m | 13.00 | -- | 5.11 | -- | 54.55 | -1.02 | -1.02 | 0.3142 | 3.15 | 0.0862 | -- | 10.59 | 581,461.60 | -27.20 | -8.36 | -29.49 | -9.10 | 82.54 | 121.50 | -315.49 | -53.37 | -- | -1,153.67 | 0.00 | -- | -60.95 | 55.82 | -1,182.15 | -- | 9.13 | -- |
| Enzymatica AB (publ) | 52.73m | -54.14m | 417.50m | 21.00 | -- | 3.08 | -- | 7.92 | -0.2257 | -0.2257 | 0.2198 | 0.559 | 0.292 | 1.26 | 4.54 | 2,510,953.00 | -29.98 | -29.10 | -31.26 | -34.48 | 63.76 | 63.82 | -102.68 | -73.32 | -- | -- | 0.0095 | -- | -10.47 | -5.76 | -6.94 | -- | -14.62 | -- |
| Moberg Pharma AB (publ) | 12.50m | -257.79m | 446.69m | 6.00 | -- | 0.6367 | -- | 35.74 | -5.52 | -5.52 | 0.2672 | 14.40 | 0.0153 | 0.9991 | 1.87 | 1,388,556.00 | -31.46 | -- | -32.04 | -- | 52.35 | -- | -2,062.80 | -- | 15.81 | -- | 0.0044 | -- | -- | -- | -1,109.46 | -- | -- | -- |
| Navamedic ASA | 506.69m | -37.04m | 493.33m | 45.00 | -- | 2.50 | -- | 0.9736 | -2.21 | -2.21 | 27.98 | 8.74 | 0.883 | 3.27 | 6.40 | 12,843,290.00 | -6.45 | -0.3087 | -8.75 | -0.4895 | 37.32 | 39.37 | -7.31 | -0.2916 | 0.7697 | 0.192 | 0.5978 | -- | 3.80 | 23.00 | 59.92 | -- | 35.76 | -- |
| Dicot Pharma AB | 126.00k | -84.00m | 640.98m | 4.00 | -- | 7.10 | -- | 5,087.15 | -0.0459 | -0.0459 | 0.00007 | 0.0449 | 0.001 | 10.68 | 0.0371 | 42,000.00 | -69.50 | -94.78 | -75.43 | -111.46 | -61,341.27 | -32,616.05 | -66,663.49 | -37,576.05 | 8.82 | -- | 0.00 | -- | -88.60 | -47.16 | -30.66 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Moberg Pharma AB (publ)'s reporting currency: Swedish Krona SEK
2.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SEB Funds ABas of 31 Dec 2025 | 414.09k | 0.85% |
| Handelsbanken Fonder ABas of 31 Dec 2025 | 285.03k | 0.59% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 244.55k | 0.50% |
| Skandia Investment Management ABas of 28 Nov 2025 | 108.14k | 0.22% |
| Skandia Fonder ABas of 28 Nov 2025 | 1.60k | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
